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Abstract
Immunogenic lipids may play key roles in host defenses against infection and in generating autoimmune 
inflammation and organ-specific damage. In multiple sclerosis (MS) there are unequivocal autoimmune features 
and vulnerability to aggravation or induction by microbial or viral infection. We have found glycolipid-driven anergy 
of circulating lymphocytes in MS indicating that this immune response is affected in MS and the robust effects of 
iNKT activation with potent cellular and cytokine activities emphasizes its potential importance. Diverse glycolipids 
including the endogenous myelin acetylated-galactosylceramides (AcGalCer) can drive activation that could be 
critical to the inflammatory demyelination in the central nervous system and clinical consequences. The iNKT cells 
and their invariant or iTCR (Vα24Jα18Vβ11) constitute an innate defense−a discrete immune arm that is separate 
from peptide-driven acquired immune responses. This offers new possibilities for insight including a likelihood that 
the pattern recognition of exogenous microbial and myelin immunogens can overlap and cross-react especially in 
an inflammatory milieu.
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Introduction 
A relatively unexplored frontier in multiple sclerosis (MS) research 
is the role of immunogenic lipids and particularly complex glycolipids 
and sphingolipids in disease mechanisms. Unlike peptides that reside 
internally, complex lipophilic molecules are on the microbial surface 
and first encounter host immune defenses in the course of infection. 
Hence, they qualify as possible “original antigens” igniting immune 
responses that can lead in the susceptible host to breaking tolerance 
and enabling autoimmune reactivity, inflammation, demyelination 
and symptomatic MS. The detailed mechanism of the development 
of intolerance is problematic but molecular over-lapping implicit in 
such suggestions as molecular mimicry [1] or polyspecificity [2] is a 
plausible means by which an ordinarily host-protective defensive 
immune response to infection (or an endogenous danger signal) is 
transformed into self-destructive attack. The slow evolution of research 
pursuing lipids as driving antigens in MS stems from their hydrophobic 
or partially hydrophobic (i.e. amphipathic) nature with solubility 
considerations that complicate assay and kinetic measurements because 
the limited aqueous solubility and molecular behavior of lipids affects 
antigen presentation as well as binding reproducibility and sensitivity.
Lipid Antigens as a Target for Autoimmune Attack in 
MS
The target organ of MS is mainly myelin though other CNS cells 
including neurons and their axons, astrocytes, microglia, endothelial 
cells or pericytes may also be affected. Our interest in the lipids of myelin 
and their established and potential roles as immunogens and bioactive 
mediators in the mechanisms of the inflammatory demyelination of 
MS has been described [3-6] and will here be only briefly summarized. 
Myelin is a unique multilayered membrane investing axons and 
facilitating saltatory conduction. Myelin is highly concentrated 
in complex lipids and sterols with an asymmetric arrangement of 
glycolipids and also phosphatidylethanolamine in the outer membrane 
[7] while phosphatidylserine predominates on the cytoplasmic face [8]. 
The main myelin lipids and other myelin constituents are depicted in 
Figure 1. Galactosylceramides (GalCer) have long been known to bind 
to CNS-derived immunoglobulins [9]. Other GalCer derivatives are 
sulfated, sialylated and acetylated; specific compounds being sulfatide 
[10], GM4 ganglioside (sialosyl-galactosylceramide) [11], GM1 
monosialganglioside and the acetyl-galactosylceramides (AcGalCer) 
[12-14]. All of these are potent immunogens as well.
MS is the most common demyelinating disease of man and seems 
to be mediated by auto-reactive CNS-specific CD4+ or other T cells 
with a role for B cells too. The demyelination is largely inflammatory 
in nature and the pathogenic events are believed to follow a sequence 
for T cells of initial priming, activation in the periphery by cytokines 
or other means, migration across the endothelial cell and blood-brain 
barrier, and re-activation during CNS invasion. There have been many 
reports describing changes in lipids in MS plaque lesions and in normal-
appearing white matter (NAWM). The main or most compelling ones 
will be briefly reviewed in the following with particular attention to 
gangliosides, sulfatides, phospholipids, and AcGalCer. In the past, 
AcGalCers have also been operationally called FMCs or fast-migrating 
cerebrosides reflecting the TLC behavior that enabled resolution 
from gluco- and galactosylceramides and purification for structural 
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characterization [15]. In MS brain total lipid content is decreased and 
myelin-enriched lipids decreased or absent. Cholesterol is decreased in 
both NAWM and normal appearing gray matter (NAGM) in MS brain 
[16]. Other tantalizing alterations in levels or molecular state (e.g. lipid 
oxidation or degradation) have been described (see below). They are 
interesting because of the effect of the molecular structural alterations 
upon immunogenicity.
Gangliosides are abundant in brain and associated with neuronal 
surface or axolemma while GM1 is increased in concentration in 
myelin. Their concentration is reduced in MS and composition altered 
such that plaques are devoid of GM4; GM1 and GM2 are reduced, and; 
GD2 & GD3 are elevated as are GQ1 and other polysialo-gangliosides 
[17]. Only minor changes in lipid concentration have been observed in 
MS white matter [18].
Sulfatides are reduced in MS plaques and less so in WM with a 
sparing of the hydroxylated species especially hC24:0 sulfatide [19].
Phospholipids (PL) are of interest in MS because anti-PL antibodies 
(aPLs) reportedly increase though not all workers found this [20,21]. 
Intriguing relevant additional observations include an elevation of 
choline in NAWM that evolves into plaque [22,23], and an increase in 
oxidized phosphatidylcholine (PC) in MS but not control brain [24].
Anti-glycolipid Reactivity in MS
Autoantibodies occur in autoimmune disorders, may be 
proportional in titer to disease severity and could be valuable markers 
for diagnosis, classification, assessment of disease activity and future 
course [25]. Roles for pathogenic antibodies are the main issue but 
protective and repair functions have been observed and at times the 
nature of the binding could not be determined. Antibody elevations 
in MS CSF affect mainly the IgG1 isotype; occasionally the antibody 
is IgG3.
For decades, effort has been directed mainly to the study of the 
immune response to proteins found in myelin [26-31] while the role of 
myelin lipids has not been strictly defined [4] until more recently when 
the determination of anti-lipid specificity has become an important 
avenue of MS research.
Of the glycolipids, GalCer, which accounts for 32% of CNS myelin 
lipid content, was mainly targeted for an auto-antibody immune 
response and recently anti-GalCer antibodies with demyelinating 
potential [32,33] have been found in MS, particularly in RRMS and 
not in healthy controls [34]. Since these antibodies are not detected 
to any extent in patients with early-stage MS in the clinically isolated 
syndrome (CIS), it would be useful to monitor CIS patients for these 
anti-GalCer antibodies in order to predict conversion to clinically 
definite MS. Antibodies in MS to other glycolipids such as gangliosides 
[35-37], sulfatides [38,39], and phospholipids [40] have been also 
described, and might be associated with disease progression. We have 
attempted to define the specificity of antibodies for complex lipids [14]. 
Consistent with reports of MS CSF antibodies determined by lipid array 
analysis the findings suggest that the oligoclonal IgGs in MS brain and 
CSF react with myelin lipids that are released during myelin breakdown 
during demyelination with antibodies that are particularly reactive 
with sulfatide, sphingomyelin, several phospholipids and oxidized 
phospholipids, and oxidized sterols [41,42]. Overall, we believe that the 
increased and oligoclonal immunoglobulin in MS CSF is directed at the 
tissue inflammatory response encompassing a range of complex lipid 
antigens that are mostly myelin lipids and with degradation products 
including bioactive signal molecules [6]. MS patients with higher IgG 
levels and polyclonality (i.e. more oligoclonal IgGs) are reported to have 
a poorer prognosis [43,44]; thus greater inflammatory response and 
greater autoimmune reactivity is ominous. Intrathecal IgM synthesis 
has also been associated with rapid MS progression and is associated 
with lipid immunogenicity particularly of phosphatidylcholine [45].
Glycolipid Ligands for iNKT Cells
Several types of regulatory cells including CD8+ T cells, B cells and 
NKT cells participate in controlling pathological autoimmunity [4]. 
We have focused upon NKT cells because the invariant NKT cells are 
glycolipid-reactive and constitute a distinct and discrete arm of the 
immune system that is separate from conventional peptide-binding 
T cells [46]. The invariant NKT (iNKT or type I NKT) cells employ 
a single species of TCR encoded by Vα24Jα18 α-chain gene segments 
in humans [47]. This iTCR binds mainly glycolipid antigens and 
requires for lipid presentation CD1d; a non-classical monomorphic 
MHC-related antigen presenting cell (APC) surface protein [47]. 
Glycosphingolipids
Oligodendrocyte
Myelin sheath
Node of Ranvier
Myelin sheath
CNP
PLP
MOG
MAG
MBP
Axon
R4O
R5O
OR6 H
FMC-1:  R1  = H, R2
FMC-2:  R1  = OH, R2
FMC-3:  R1  = H, R2
FMC-4:  R1  = OH, R2
FMC-6:  R1  = OH, R2-R6
FMC-7:  R1  = OAc, R2-R6
FMC-5:  R1  = H, R2-R6
OR2
OR3
O
O
n1
n2
R1
O
H
N H
=
=
=
=
=
=
=
Ac, R3-R6 =H ;
Ac, R3-R6 =H ;
Ac, R3 = Ac, R4-R6 =H;
Ac, R3 = Ac, R4-R6 = H;
Ac;
Ac;
Ac;
Figure 1: A composite diagram summarizing features of CNS myelin: 
i). architecture of CNS myelin; ii) molecular composition of CNS myelin 
(three-dimensional view) and; iii.) the unique sphingosine 3-O-acetylated-
GalCer glycolipid series. The myelin is a multi-layer membrane formed by 
oligodendrocytes, containing a high lipid (80%) to protein (20%) ratio and 
an asymmetric distribution of lipids (PLP: Proteolipid protein; MBP: Myelin 
basic protein; MOG: Myelin oligodendrocyte glycoprotein; MAG: Myelin-
associated glycoprotein; CNP: 2’3’-cyclic-nucleotide 3’-phospodiesterase). 
The diagram depicts a hypothetical arrangement according to molar 
compositions of complex lipids (cholesterol, phospholipids and glycolipids) 
and the most abundant proteins (PLP, MBP) in the CNS myelin bilayer. The 
relative constancy of molar proportions of the three lipid classes: cholesterol 
(C): phospholipids (PL): galactocerebrosides (GalCer) distributed in bilayers 
is C: PL: GalCer=2:2:1. Proteins abbreviated as above are marked in yellow 
and the comprising lipids are as follows: cholesterol in orange, phospholipids 
in pink and the glycosphingolipids (FMC: Fast migrating cerebrosides; 
GalCer: Galactosylceramide; GM1: Mono-sialoganglioside; GM4: Sialosyl-
galactosylceramide; sGalCer: sulfatide) in blue.
Structures of myelin acetyl-cerebrosides (FMCs) are shown at the top. Seven 
GalCer derivatives, have been characterized in vertebrate brain myelin 
including human. FMC-1-2 are 3-O- acetyl-sphingosine derivatives, FMC-3 
-4 add 6-O-acetyl-galactose, and the complex FMC-5-6-7 are 2,3,4,6-tetra-O-
acetyl-GalCers. Penta- and hexa-acetylated complex FMCs are hydrophobic 
lipids capable of affecting myelin membrane curvature, lipid interactions, and 
immune reactivity.
Adapted and modified from Podbielska et al. [5].
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The breadth of molecules reacting with the iNKT receptor (iTCR) 
categorizes the iTCR as an innate pathogen recognition receptor 
(PRR). The crystal structure of the complex formed by the potent 
ligand α-galactosylceramide (α-GalCer), human CD1d and the iTCR 
(Vα24Vβ11) has been characterized and shows binding sites for both 
the GL ligand and CD1d on the iTCR α-chain [48]. Both the iTCR and 
CD1d are conserved emphasizing the importance of NKTs in man. The 
binding reactivity of the invariant TCR encompasses many glycolipids 
[49] that prime the iNKT cell for activation mainly by cytokines 
including IL-12, IL-10 and IL-17 for diverse activation. Prominent 
immune responses include the following: (i.) Th1-biased inflammation, 
(ii.) regulatory T cell maturation, and (iii.) pathogen defense [46] 
and we have depicted a scheme (Figure 2) to outline the GL ligand/
iTCR binding and subsequent T cell priming and then activation in 
different ways as determined and mediated by the local environment. 
Conserved cytokine activation and diversification in MS for these 
and related cytokines has long been recognized [50]. INKT cells are 
cytokine-rich, potent and versatile, and the iNKT cell interface with 
innate GL conformational signals for infections or for intrinsic dangers 
is a transformational bridge able to elicit specific cytokine messaging 
by IL-1, TNF-α, IL-12, IL-17 and others en route to specific responses 
by the acquired immune system. INKT cells produce large amounts of 
IFN-γ and IL-4 upon activation particularly by α-GalCer [51,52] and 
have diverse effects in vivo including regulation of autoimmunity [53].
We examined iNKT cell function (Figure 3) in circulating 
peripheral blood cells in MS patients.
In recent years an important role for T-cells that bear natural killer 
(NK) receptors has been recognized in regulating autoimmune diseases 
like MS [54,55]. Included in this group are the invariant NKT-cells 
that express NK-cell surface receptors and a highly restricted T-cell 
receptor (TCR) repertoire, encoded by Vα24 and Jα18 genes in humans 
[46,47]. INKT and other innate immune cells like γδ T-cells [56] act 
as front-line immune regulatory cells [54]. Because these T-cells 
play important roles in regulating human autoimmune diseases, we 
quantified T-cells populations expressing the NKR CD56, CD161 
and CD94 in the peripheral blood of MS patients, in healthy control 
subjects (HS) and in patients with other neurological diseases (OND) 
[57] and showed that populations of CD161+ T-cells and CD94+ T-cells 
were significantly decreased in MS patients with primary progressive 
disease and secondarily progressive disease respectively whereas CD56+ 
T-cell numbers were unchanged. In contrast NKT-cells expressing the 
invariant Vα24Jα18+ T-cell receptor identified by specific receptor 
antibody and CD1d-tetrameric PBS57-loaded complexes, were 
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Figure 2: iNKT cell-mediated responses in the immune system. Several different antigenic GLs: microbial GLs; danger ligands as from cellular oxidation; and self 
antigens (in MS case they are myelin GLs) compete for binding to iTCR. The iTCR is a PRR that are ’pattern recognition receptors’ of the innate immune system. This 
recognition allows immune responses to different lipids–e.g. GLs, PLs and these can allow immune responses to microbial GLs (usually with high affinity) to overlap 
with those to self Ags (weaker affinity as a rule). The iNKT is 1) primed by the GL/iTCR/Cd1d receptor-located interaction or interface, and then 2) respond in one 
of several ways according to the environment, mainly cytokines-dependent. This affects control of diverse outcomes: i) pro-inflammatory (Th-1 type responses), ii) 
regulatory (Th-2 type responses) or iii) anti-pathogen (Th-17 type responses). Initial and subsequent interaction with IL-12 leads to iNKT pro-inflammatory functions. 
IL-12-activated iNKT mediate adjuvant activity by their production of IFN-γ, which in turn activates both innate and acquired immune systems. In contrast, interaction 
with an IL-10-driven response generates regulatory Tr1 Treg (e.g. CD4+CD25+Foxp3) that are charged with development and maintaining tolerance. In addition to 
their roles in autoimmunity and tolerance, iNKT cells have also anti-pathogen activity triggered by IL-17 and IL-23. Adapted and modified from Taniguchi et al. [46].
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a decrease in immune inhibition with consequent progression of the 
neurodegenerative phase of MS. We also employed flow cytometry and 
cytokine assay to study the functional responses of the NKR+ T cells 
to stimulation with α-GalCer and to two myelin-derived glycolipids 
that are poly-acetylated derivatives of β-galactosylceramide designated 
as fast-migrating cerebrosides (FMC) [59]. In healthy subjects, FMC 
stimulation of peripheral blood cells significantly expanded iNKT-cells 
similar to α-GalCer and induced significant increases in Th1, Th2 and 
Th17 cytokines. Importantly, the glycolipid response as measured by 
an expansion in cell number was specific to the iNKT-cell population: 
there were no increases in the frequencies of either NK cells or NKR+ 
T-cells (CD56+ T-cells, CD161+ T-cells and CD94+ T-cells) upon 
stimulation with any of the glycolipids tested. The results with MS 
patients were in striking contrast to healthy control subjects. INKT-
cells from MS patients failed to respond to FMCs or to α-GalCer 
stimulation indicating an anergic response. We propose then that 
myelin-derived FMC glycolipids stimulate iNKT-cell responses in vivo 
and this is blocked in MS. Rendering iNKT-cells hyporesponsive to 
an endogenous glycolipid is a novel insight into diseases manifesting 
aberrant iNKT-cell activation and consequently this finding of 
glycolipid ligand-driven anergy in MS has substantial implications 
for MS. The loss of responsiveness or anergy was to the exogenous 
α-GalCer ligand [57] as well as to the endogenous polyacetylated-
GalCers (FMCs) [59] that we had previously purified and characterized 
[14]. Furthermore the numbers of iNKT cells significantly expanded 
upon stimulation with α-GalCer and the FMCs accompanied by 
robust cytokine secretion in healthy control subjects [57,59]. These 
included cytokines associated with Th1 cells (IFN-γ), Th17 cells (IL-
17, TNF-α) and both pro-inflammatory (IL-1b, IL-6, TNF-α) and anti-
inflammatory responses (IL-10). IL-17 expression is upregulated and 
involved in the pathogenesis of MS in humans [60] and also in EAE 
[61].
Since α-GalCer ameliorates or prevents EAE [62,63] and another 
innate indicator, activation of γδ T cells by lipid antigens, rises in 
MS [64], implications for MS mechanisms are likely. The anergy 
that is consistent with previous iNKT cell usage, implicates innate 
iNKT immune reactivity and probably reflects saturation of the 
iTCR by glycolipid antigen due to infection or to release of myelin 
glycolipids during MS demyelination. We think as outlined in Figure 
2 that the rivalry at the receptor level of high-iTCR-affinity microbial 
glycolipids with weaker-binding myelin glycolipids initiates iNKT 
cell activation that depends upon the presence of cytokines mediating 
either damaging Th1-biased (Il-12 driven) or pathogen directed (IL-
23 & IL-10 driven), or regulatory T cell (Tr-1 cells) processes [46]. 
The scheme admittedly simplifies the complexity of the cytokine and 
other influential controls but allows for plausible hypotheses for the 
transformation of an infection-dependent process to an autoimmune 
one with loss of tolerance for endogenous myelin biomarkers. It also 
provides a basis for examining the inflammation and other events 
underlying MS’s complicated pathogenesis. Our scheme for the 
sequences of GL-reactivity and iNKT-mediated consequences that 
occur in MS CNS stresses competition for GL antigens that underlies 
the cross-reactivity that allows tolerance for self myelin lipid antigens 
to be broken and then for myelin-targeted inflammation directed by 
local environmental signals especially IL-12, -10, -23 and -17. Pursuing 
the glycolipid and lipid-specific cells in MS will yield insights into lipid 
use in anti-microbial vaccines and whether CD1d-restricted T cell 
strategies can treat MS.
increased in MS patients compared with healthy subjects. Alterations 
in the proportions of NKR+ T-cells in MS may be clinically relevant 
since reduced numbers could insufficiently activate populations 
required for controlling disease activity: this has been shown for 
the functional activities of NKR+ T-cells in tumour immunity [58]. 
Importantly, the reductions in these NKR+ T cell numbers may reflect 
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Figure 3: NKT-cell responses to α-GalCer are impaired in MS. (A) 
Representative flow cytometric profiles of Vα24Jα18+ T-cells (NKT-cells) 
from one healthy subject (HS) and one MS patient. The frequency of NKT-
cells before and after culture with α-GalCer is shown in the upper upper-right 
hand quadrants in each plot. (B) Percentages of NKT-cells in unstimulated 
(medium alone) and α-GalCer stimulated cultures in 8 healthy subjects and 7 
MS patients. Horizontal bars indicate median levels. (C) IFN-γ production in 
unstimulated PBMC cultures or in α-GalCer stimulated cultures in HS and MS 
patients. Data shows mean levels and error bars show the standard deviation. 
Significance values comparing HS to MS patients are shown by ***, P<0.001. 
From O’Keeffe et al. [57].
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a context of genetic and environmental factors that are complex and not 
fully understood but with key roles for both determinants, microbial 
triggering of autoimmunity occurs when the usual immune defense 
against pathogenic microbes with concurrent tolerance for myelin 
antigens loses non-self/self discrimination and allows myelin antigens 
to react with host immune elements and produce myelin-specific 
inflammation and damage. The conformational plasticity of complex 
lipids and especially glycolipids suffices for the range of an innate 
pattern recognition receptor the iTCR, Vα24Jα18Vβ11, and allows 
overlapping molecular diversity with consequent loss of tolerance 
leading to maladaptive organ-specific inflammation affecting CNS 
and particularly myelin. Our studies of the glycolipid-reactive separate 
immune arm mediated by iNKT cells that revealed anergy of circulating 
lymphocytes in MS to the potent exogenous stimulant α-GalCer now 
extend to endogenous myelin lipid antigens; the acetyl-β-GalCer series. 
The indication that utilization of the iNKT pathway is a feature of the 
infection-MS transition linking infection and autoimmune disorder not 
only offers novel insight into MS pathogenesis but may also have more 
fundamental importance indicating a mechanism for organ glycolipids 
to initiate induction of numerous other organ-targeted autoimmune 
disorders such as myasthenia gravis and rheumatoid arthritis. To us 
the prospect of gaining molecular insight into the mechanism of the 
infectious trigger adds welcome light to the darkness enveloping the 
enigmatic and disabling scourge MS.
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The Glycolipid-iNKT Pathway Can Trigger Infection-
related Autoimmune Disorder
The evidence the MS is triggered by infection is both clinical with 
an increased frequency of infection in conjunction with relapse [65-
67] and laboratory-based demonstration of infectious agents [68,69] 
and supports an interpretation that infection precipitates or activates 
CNS inflammation in MS. Antibodies to many viruses and bacteria 
[70-75] and reactivity of lymphocytes [76-79] have been examined, 
and reactivity with measles, mumps, herpes (HSV-1), varicella (VZV), 
cytomegalovirus (CMV), and Epstein-Barr virus (EBV) [70-75] have 
been reported though titers and affinities for these have been low, and 
the binding specificity of the majority of intrathecal antibody in MS is 
not known. Taken together it appears clear that systemic infections may 
trigger a relapse or exacerbate existing symptoms of multiple sclerosis.
Molecular overlap and consequent cross-reactivity also occurs in 
several other immune-mediated inflammatory neurological disorders 
involving peripheral nervous system (PNS). In these disorders there 
is relatively strong experimental support for a role of glycolipid and 
particularly the glycose moiety as immunogenic. Immune mechanisms 
play a crucial part in Guillain-Barré syndrome (GBS) pathogenesis. 
About two-thirds of GBS patients have symptoms of an infection in the 
3 weeks before the onset of weakness. The most frequently identified 
infection is Campylobacter jejuni. Other specifically characterized 
types of infection related to GBS are cytomegalovirus, Epstein-
Barr virus, Mycoplasma pneumonia and Haemophilus influenza. In 
about half of patients with GBS and the clinical variant syndromes 
in the forms of: (a.) acute motor axonal neuropathy [acute motor 
axonal neuropathy (AMAN) or (b.) acute motor and sensory axonal 
neuropathy (AMSAN)] and (c.) a cranial nerve variant of GBS, 
Miller Fisher syndrome (MFS) [80]. Serum antibodies have been 
observed in GBS and related disorders to various gangliosides that 
have been found in human peripheral nerves, including LM1, GM1, 
GM1b, GM2, GD1a, GalNAc-GD1a, GD1b, GD2, GD3, GT1a and 
GQ1b. Other antibodies bind to mixtures or complexes of different 
gangliosides instead of binding individual gangliosides. Interestingly, 
most of these antibodies are specific to defined subtypes of GBS. 
Antibodies to GM1, GM1b, GD1a and GalNAc-GD1a are associated 
with pure motor or axonal neuropathy (AMAN or AMSAN), whereas 
antibodies to GD3, GT1a and GQ1b are related to the MFS variant 
form of acute inflammatory GBS neuropathy affecting control of eye 
movement (ophthalmoplegia) [80]. In addition, GBS is more severe 
when antibodies against GM1 are found. Clinical examples of this are 
chronic inflammatory demyelinating polyneuropathy (CIDP) with 
anti-GM1 and LM1 antibodies [80] and multifocal motor neuropathy 
(MMN) with 33% manifesting IgM antibodies against GM1 and GM1a. 
Another PNS example is sensory neuropathy with antibodies to GD1b 
and disialogangliosides. C. jejuni isolates from patients with pure 
motor or axonal GBS frequently express a GM1-like and GD1a-like 
glycol-eiptopes on liposaccharides (LPS), whereas those isolated from 
patients with ophthalmoplegia or MFS usually express a GD3-like, 
GT1a-like, or GD1c-like LPS. Antibodies in these patients are usually 
cross-reactive, and recognize LPS as well as gangliosides or ganglioside 
complexes strongly suggesting that molecular mimicry of PNS myelin 
gangliosides and microbial LPS is a mechanism of the autoimmune 
neuropathy [81].
A Future Perspective
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